Raymond James & Associates’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Raymond James & Associates’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$370	–	4101
2023 Q4	$370	Hold	10,000	–	–	﹤0.01%	3821
2023 Q3	$3.98K	Sell	10,000 -1,097	-10%	-$540	﹤0.01%	3779
2023 Q2	$7.66K	Buy	+11,097	New	+$71.5K	﹤0.01%	3817
2020 Q1	–	Sell	-1,635	Closed	-$9K	–	3837
2019 Q4	$9K	Buy	+1,635	New	+$10.4K	﹤0.01%	3638

Raymond James & Associates's BLPH Position: Q1 2024 in Review

Raymond James & Associates sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2024, closing a stake of 10,000 shares — an estimated $370 sold.

Raymond James & Associates first reported a position in BLPH in Q4 2019 and held it in 4 quarters. The position peaked at $9K in Q4 2019. 0 funds tracked by Wall St. Rank hold BLPH as of Q1 2024.

Raymond James & Associates reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
Raymond James & Associates sold 10,000 Bellerophon Therapeutics, Inc. shares in Q1 2024, an estimated $370.
Raymond James & Associates first reported a position in Bellerophon Therapeutics, Inc. in Q4 2019 and held it in 4 quarters.
Raymond James & Associates's Bellerophon Therapeutics, Inc. position peaked at $9K in Q4 2019.
0 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.